Incidence and Risk Factors for Varicella-Zoster Virus-Associated Central Nervous System Infections: A Nationwide Swedish Retrospective Case-Control Study
- PMID: 39865326
- PMCID: PMC11771675
- DOI: 10.1002/jmv.70166
Incidence and Risk Factors for Varicella-Zoster Virus-Associated Central Nervous System Infections: A Nationwide Swedish Retrospective Case-Control Study
Abstract
The determinants of varicella-zoster virus (VZV)-associated central nervous system (CNS) infection have not been fully elucidated. This study aimed to investigate the incidence and risk factors, including immunosuppression, for different manifestations of VZV-associated CNS infection. Patient registers were used to include adults diagnosed with VZV-associated CNS infections between 2010 and 2019 in Sweden. Nationwide registers covering specialized care, and regional registers covering primary care, were used. Controls without a VZV diagnosis during the study period were matched by age and sex. Risk factors were calculated using multivariable logistic regression. A total of 1488 adult cases with VZV-associated CNS infection were identified, yielding an incidence of 1.92/100 000 person-years, which increased over the study period. Meningitis was the most frequent (45%), followed by encephalitis (38%), and Ramsay Hunt syndrome (17%). The highest incidence was observed in individuals over 70 years of age (4.15/100 000 person-years), in whom encephalitis was most common. Statistically significant risk factors for VZV-associated CNS infection were HIV, hematological cancer, treatment with specific immunosuppressants or glucocorticoids, chronic obstructive pulmonary disease, diabetes, solid cancer, stroke, and congestive heart failure. Encephalitis was associated with older age, more immunosuppressive conditions, and more comorbidities than other manifestations. In conclusion, VZV is a common cause of adult viral CNS infection, for which elderly individuals with immunosuppressive or comorbid conditions are at the highest risk. The strongest risk factors found were HIV, hematological cancer, and treatment with specific immunosuppressants or high-dose glucocorticoids.
Keywords: central nervous system (CNS); encephalitis; epidemiology; immunosuppression; varicella‐zoster virus (VZV).
© 2025 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.
Conflict of interest statement
GlaxoSmithKline Biologicals SA provided funding and advisory support in this collaboration study, but the authors are fully responsible for the design, data collection, analyses, and interpretation of results. LH has given lectures at GlaxoSmithKline, Pfizer, and Bavarian Nordic. The other authors declare no conflict of interests.
Figures
References
-
- Granerod J., Ambrose H. E., Davies N. W., et al., “Causes of Encephalitis and Differences in Their Clinical Presentations in England: A Multicentre, Population‐Based Prospective Study,” Lancet Infectious Diseases 10, no. 12 (December 2010): 835–844. - PubMed
-
- Koskiniemi M., Rantalaiho T., Piiparinen H., et al., “Infections of the Central Nervous System of Suspected Viral Origin: A Collaborative Study From Finland,” Journal of Neurovirology 7, no. 5 (October 2001): 400–408. - PubMed
-
- Mailles A., De Broucker T., Costanzo P., et al., “Long‐Term Outcome of Patients Presenting With Acute Infectious Encephalitis of Various Causes in France,” Clinical Infectious Diseases 54, no. 10 (May 2012): 1455–1464. - PubMed
-
- Persson A., Bergström T., Lindh M., Namvar L., and Studahl M., “Varicella‐Zoster Virus CNS Disease‐‐Viral Load, Clinical Manifestations and Sequels,” Journal of Clinical Virology 46, no. 3 (November 2009): 249–253. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
